GILD vs REGN
GILD and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $208.51B | — |
| P/E (TTM) | 24.8 | 21.3 |
| P/B | 15.99 | — |
| P/S | 7.2x | — |
| Dividend yield | 1.92% | — |
| Revenue | $30.99B(TTM) | $16.90B(TTM) |
| Revenue growth (YoY) | 2.4% | 1.0% |
| Net income | -$3.86B(TTM) | $4.82B(TTM) |
| Earnings growth (YoY) | 1672.9% | 2.1% |
| EPS, diluted | $-3.13(TTM) | $45.24(TTM) |
| EBIT margin | 34.0% | 24.9% |
| ROE | 65.3% | 13.4% |
| ROIC | 25.7% | 9.2% |
| 1y total return | +44.5% | +48.3% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: GILD frente a REGN
| Métrica | GILD | REGN |
|---|---|---|
| Valor final | $28.8K | $27.8K |
| Retorno total | +187.9% | +178.0% |
| CAGR | +10.8% | +10.4% |
| Volatilidad | 25.6% | 32.3% |
| Sharpe | 0.37 | 0.34 |
| Sortino | 0.55 | 0.50 |
| Caída máxima | -30.5% | -59.7% |
Basado en 2600 días de negociación comunes, 2016-06-30 → 2026-11-02 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)